ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Vedanta Biosciences raised $60 million in funding. The company will use the capital to advance its microbiome-based drug development pipeline. The financing round supports ongoing clinical programs and operational growth.
Tap to vote and see what everyone thinks.
Summary by ByteBrief